Maud de Dieuleveult
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maud de Dieuleveult has a total of 392 co-authors. Here are the top co-authors by number of shared publications:
- Benoit Miotto
Université Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France
6 shared publications - Fayçal Boussouar
Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences
3 shared publications - Matthieu Gérard
Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC)
3 shared publications Anne-Claire Richard
Department of Genetics and Reference Center for Developmental Abnormalities, University Rouen Normandie, Normandie University, Inserm U1245 and CHU Rouen, Rouen, France
2 shared publicationsAurélie Coussement
Fédération de Génétique Et Médecine Génomique, Service de Médecine Génomique Des Maladies de Système Et d’Organes, AP-HP, Hôpital Cochin, Paris, France
2 shared publicationsChao Li
Max Born Crescent, Institute of Cell Biology, University of Edinburgh, Edinburgh, UK
2 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 482
MAKAAO, an open access resource linking human autoantibodies and autoimmune diseases
- 14 September 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 482
Open AccessMAKAAO, an open access resource linking human autoantibodies and autoimmune diseases
- Open Access
- 8 April 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Identification of an episignature for CHD3-related Snijders Blok-Campeau syndrome reveals heterogeneity in the CHARGE syndrome episignature: towards a better characterisation of chromatinopathies
Recent advances in sequencing technologies have enhanced patient diagnosis; however, causal pathogenic variants remain unidentified for a significant numbe
- 8 April 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Open AccessIdentification of an episignature for CHD3-related Snijders Blok-Campeau syndrome reveals heterogeneity in the CHARGE syndrome episignature: towards a better characterisation of chromatinopathies
Recent advances in sequencing technologies have enhanced patient diagnosis; however, causal pathogenic variants remain unidentified for a significant numbe
- Open Access
- 26 May 2025
- Published by Springer Nature in Research Square
Identification of an episignature for CHD3-related Snijders Blok-Campeau syndrome reveals heterogeneity in the CHARGE syndrome episignature: towards a better characterization of chromatinopathies.
Recent advances in sequencing technologies have enhanced patient diagnosis; however, causal pathogenic variants remain unidentified for a significant number of patients due to limited understanding of certain variants, regulatory sequences, or sequencing challenges, such as complex rearrangements. Investigating the epigenetic landscape has become essential to improve the diagnostic yield. Diseases caused by pathogenic variants in epigenetic regulators, often associated with growth abnormalities, intellectual disability, and facial dysmorphism, are prime models for studying episignatures. Among them, Snijders Blok-Campeau syndrome (ORPHA:599082), caused by pathogenic variants in the CHD3 gene, remains largely understudied. A European cohort of 22 patients displaying typical Snijders Blok-Campeau syndrome traits and carrying pathogenic/likely pathogenic CHD3 variants was analysed using the Illumina EPIC array, identifying 139 differentially methylated positions distinguishing patients from 79 healthy matched controls. These regions serve as diagnostic tools for complex cases or variants of uncertain significance and help uncover deregulated pathways linked to this syndrome. Three patients carrying pathogenic/likely pathogenic variants but atypical clinical presentation as well as 5 patients with variants of uncertain significance were analysed as testing set. Comparing methylomes of patients carrying pathogenic variants in CHD3, CHD7 (CHARGE syndrome, ORPHA:138), or CHD8 (Intellectual developmental disorder with autism and macrocephaly, ORPHA:642675) genes allows us to identify distinct subgroups with unique methylation profiles. This robust CHD3 DNA methylation signature aids in reclassifying variants and diagnosing atypical cases. Our findings advance the field of epigenetic signatures in rare diseases. We have opened new avenues for further investigation into subtypes defined by methylome assays (such as in the context of chromatinopathies) which could refine the phenotype spectrum and help predict patient outcomes.
- 26 May 2025
- Published by Springer Nature in Research Square
Open AccessIdentification of an episignature for CHD3-related Snijders Blok-Campeau syndrome reveals heterogeneity in the CHARGE syndrome episignature: towards a better characterization of chromatinopathies.
Recent advances in sequencing technologies have enhanced patient diagnosis; however, causal pathogenic variants remain unidentified for a significant number of patients due to limited understanding of certain variants, regulatory sequences, or sequencing challenges, such as complex rearrangements. Investigating the epigenetic landscape has become essential to improve the diagnostic yield. Diseases caused by pathogenic variants in epigenetic regulators, often associated with growth abnormalities, intellectual disability, and facial dysmorphism, are prime models for studying episignatures. Among them, Snijders Blok-Campeau syndrome (ORPHA:599082), caused by pathogenic variants in the CHD3 gene, remains largely understudied. A European cohort of 22 patients displaying typical Snijders Blok-Campeau syndrome traits and carrying pathogenic/likely pathogenic CHD3 variants was analysed using the Illumina EPIC array, identifying 139 differentially methylated positions distinguishing patients from 79 healthy matched controls. These regions serve as diagnostic tools for complex cases or variants of uncertain significance and help uncover deregulated pathways linked to this syndrome. Three patients carrying pathogenic/likely pathogenic variants but atypical clinical presentation as well as 5 patients with variants of uncertain significance were analysed as testing set. Comparing methylomes of patients carrying pathogenic variants in CHD3, CHD7 (CHARGE syndrome, ORPHA:138), or CHD8 (Intellectual developmental disorder with autism and macrocephaly, ORPHA:642675) genes allows us to identify distinct subgroups with unique methylation profiles. This robust CHD3 DNA methylation signature aids in reclassifying variants and diagnosing atypical cases. Our findings advance the field of epigenetic signatures in rare diseases. We have opened new avenues for further investigation into subtypes defined by methylome assays (such as in the context of chromatinopathies) which could refine the phenotype spectrum and help predict patient outcomes.
- Open Access
- 20 December 2024
- Published by EDP Sciences in médecine/sciences
- Vol. 40 (12) , 914-924
Les maladies génétiques de la machinerie épigénétique
Le développement des technologies de séquençage et leur accessibilité accrue dans les services hospitaliers et les laboratoires de génétique a considérablement accéléré l’identification de variants génétiques associés aux maladies rares. Parmi celles-ci, les maladies génétiques de la machinerie épigénétique (MGME) se caractérisent par la présence de mutations dans des gènes codant des régulateurs épigénétiques qui jouent un rôle clé dans le développement de l’organisme et les fonctions cellulaires. En conséquence, la perte de fonction de ces régulateurs entraînerait des modifications de l’épigénome affectant profondément l’expression du génome et l’identité cellulaire. À ce titre, des perturbations du profil de méthylation de l’ADN ont été décrites dans plusieurs MGME et constituent d’ores et déjà un outil reconnu d’aide au diagnostic. L’enjeu est maintenant de savoir si et comment ces altérations de l’épigénome sont à l’origine des manifestations cliniques chez les patients atteints de cette classe particulière de maladies monogéniques. Ainsi, l’étude des MGME peut nous éclairer sur l’importance du rôle de l’épigénétique en santé, notamment sur les mécanismes impliqués dans l’émergence et la compréhension de maladies complexes comme les maladies neurodéveloppementales ou les cancers.
- 20 December 2024
- Published by EDP Sciences in médecine/sciences
- Vol. 40 (12) , 914-924
Open AccessLes maladies génétiques de la machinerie épigénétique
Le développement des technologies de séquençage et leur accessibilité accrue dans les services hospitaliers et les laboratoires de génétique a considérablement accéléré l’identification de variants génétiques associés aux maladies rares. Parmi celles-ci, les maladies génétiques de la machinerie épigénétique (MGME) se caractérisent par la présence de mutations dans des gènes codant des régulateurs épigénétiques qui jouent un rôle clé dans le développement de l’organisme et les fonctions cellulaires. En conséquence, la perte de fonction de ces régulateurs entraînerait des modifications de l’épigénome affectant profondément l’expression du génome et l’identité cellulaire. À ce titre, des perturbations du profil de méthylation de l’ADN ont été décrites dans plusieurs MGME et constituent d’ores et déjà un outil reconnu d’aide au diagnostic. L’enjeu est maintenant de savoir si et comment ces altérations de l’épigénome sont à l’origine des manifestations cliniques chez les patients atteints de cette classe particulière de maladies monogéniques. Ainsi, l’étude des MGME peut nous éclairer sur l’importance du rôle de l’épigénétique en santé, notamment sur les mécanismes impliqués dans l’émergence et la compréhension de maladies complexes comme les maladies neurodéveloppementales ou les cancers.
- Top Cited PapersOpen Access
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
The Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
Top Cited PapersOpen AccessThe Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- 7 May 2021
- Published by Taylor & Francis in Epigenetics
- Vol. 17 (4) , 422-443
The chromatin remodelling protein LSH/HELLS regulates the amount and distribution of DNA hydroxymethylation in the genome
Ten-Eleven Translocation (TET) proteins convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) leading to a dynamic epigenetic state of DNA that can influence transcription and chromatin organization. While TET proteins interact with complexes involved in transcriptional repression and activation, the overall understanding of the molecular mechanisms involved in TET-mediated regulation of gene expression still remains limited. Here, we show that TET proteins interact with the chromatin remodelling protein lymphoid-specific helicase (LSH/HELLS) in vivo and in vitro. In mouse embryonic fibroblasts (MEFs) and embryonic stem cells (ESCs) knock out of Lsh leads to a significant reduction of 5-hydroxymethylation amount in the DNA. Whole genome sequencing of 5hmC in wild-type versus Lsh knock-out MEFs and ESCs showed that in absence of Lsh, some regions of the genome gain 5hmC while others lose it, with mild correlation with gene expression changes. We further show that differentially hydroxymethylated regions did not completely overlap with differentially methylated regions indicating that changes in 5hmC distribution upon Lsh knock-out are not a direct consequence of 5mC decrease. Altogether, our results suggest that LSH, which interacts with TET proteins, contributes to the regulation of 5hmC levels and distribution in MEFs and ESCs.
- 7 May 2021
- Published by Taylor & Francis in Epigenetics
- Vol. 17 (4) , 422-443
The chromatin remodelling protein LSH/HELLS regulates the amount and distribution of DNA hydroxymethylation in the genome
Ten-Eleven Translocation (TET) proteins convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) leading to a dynamic epigenetic state of DNA that can influence transcription and chromatin organization. While TET proteins interact with complexes involved in transcriptional repression and activation, the overall understanding of the molecular mechanisms involved in TET-mediated regulation of gene expression still remains limited. Here, we show that TET proteins interact with the chromatin remodelling protein lymphoid-specific helicase (LSH/HELLS) in vivo and in vitro. In mouse embryonic fibroblasts (MEFs) and embryonic stem cells (ESCs) knock out of Lsh leads to a significant reduction of 5-hydroxymethylation amount in the DNA. Whole genome sequencing of 5hmC in wild-type versus Lsh knock-out MEFs and ESCs showed that in absence of Lsh, some regions of the genome gain 5hmC while others lose it, with mild correlation with gene expression changes. We further show that differentially hydroxymethylated regions did not completely overlap with differentially methylated regions indicating that changes in 5hmC distribution upon Lsh knock-out are not a direct consequence of 5mC decrease. Altogether, our results suggest that LSH, which interacts with TET proteins, contributes to the regulation of 5hmC levels and distribution in MEFs and ESCs.
- 1 April 2021
- Published by Elsevier in Environmental Research
- Vol. 195, 110317
Assessing the consequences of environmental exposures on the expression of the human receptor and proteases involved in SARS-CoV-2 cell-entry
- 1 April 2021
- Published by Elsevier in Environmental Research
- Vol. 195, 110317
Assessing the consequences of environmental exposures on the expression of the human receptor and proteases involved in SARS-CoV-2 cell-entry
- Open Access
Molecular and Clinical Relevance of ZBTB38 Expression Levels in Prostate Cancer
Prostate cancer is one of the most commonly diagnosed cancers in men. A number of genomic and clinical studies have led to a better understanding of prostate cancer biology. Still, the care of patients as well as the prediction of disease aggressiveness, recurrence and outcome remain challenging. Here, we showed that expression of the gene ZBTB38 is associated with poor prognosis in localised prostate cancer and could help discriminate aggressive localised prostate tumours from those who can benefit only from observation. Analysis of different prostate cancer cohorts indicates that low expression levels of ZBTB38 associate with increased levels of chromosomal abnormalities and more aggressive pathological features, including higher rate of biochemical recurrence of the disease. Importantly, gene expression profiling of these tumours, complemented with cellular assays on prostate cancer cell lines, unveiled that tumours with low levels of ZBTB38 expression might be targeted by doxorubicin, a compound generating reactive oxygen species. Our study shows that ZBTB38 is involved in prostate cancer pathogenesis and may represent a useful marker to identify high risk and highly rearranged localised prostate cancer susceptible to doxorubicin.
Open AccessMolecular and Clinical Relevance of ZBTB38 Expression Levels in Prostate Cancer
Prostate cancer is one of the most commonly diagnosed cancers in men. A number of genomic and clinical studies have led to a better understanding of prostate cancer biology. Still, the care of patients as well as the prediction of disease aggressiveness, recurrence and outcome remain challenging. Here, we showed that expression of the gene ZBTB38 is associated with poor prognosis in localised prostate cancer and could help discriminate aggressive localised prostate tumours from those who can benefit only from observation. Analysis of different prostate cancer cohorts indicates that low expression levels of ZBTB38 associate with increased levels of chromosomal abnormalities and more aggressive pathological features, including higher rate of biochemical recurrence of the disease. Importantly, gene expression profiling of these tumours, complemented with cellular assays on prostate cancer cell lines, unveiled that tumours with low levels of ZBTB38 expression might be targeted by doxorubicin, a compound generating reactive oxygen species. Our study shows that ZBTB38 is involved in prostate cancer pathogenesis and may represent a useful marker to identify high risk and highly rearranged localised prostate cancer susceptible to doxorubicin.
- Open Access
The chromatin remodeler LSH controls genome-wide cytosine hydroxymethylation
TET proteins convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), leading to a dynamic epigenetic state of DNA that can influence transcription. While TET proteins have been associated with either epigenetic repression or activation complexes, the overall understanding of the molecular mechanisms involved in TET-mediated regulation of gene transcription still remains limited. Here, we show that TET proteins interact with lymphoid-specific helicase (LSH), a chromatin remodeling factor belonging to the SNF2 super family. Lsh knock-out leads to a significant reduction of 5-hydroxymethylation global level in mouse embryonic fibroblasts (MEFs) and in embryonic stem cells (ESC). Whole genome sequencing of 5hmC in wild-type versus Lsh knock-out MEFs and ESCs showed that in absence of Lsh, some regions of the genome gain 5hmC while others lose it, with not much effect on gene expression. We further show that 5hmC modifications upon Lsh loss is not a direct consequence of 5mC decrease, as differentially hydroxymethylated regions (DhMR) did not overlap with DMR (differentially methylated regions), underlying that these modifications occurred at different genomic loci. Altogether, our results suggest that LSH is a key regulator of 5hmC in both MEFs and ESC and that TET proteins rely on specific factors to establish genome-wide 5hmC patterns.
Open AccessThe chromatin remodeler LSH controls genome-wide cytosine hydroxymethylation
TET proteins convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), leading to a dynamic epigenetic state of DNA that can influence transcription. While TET proteins have been associated with either epigenetic repression or activation complexes, the overall understanding of the molecular mechanisms involved in TET-mediated regulation of gene transcription still remains limited. Here, we show that TET proteins interact with lymphoid-specific helicase (LSH), a chromatin remodeling factor belonging to the SNF2 super family. Lsh knock-out leads to a significant reduction of 5-hydroxymethylation global level in mouse embryonic fibroblasts (MEFs) and in embryonic stem cells (ESC). Whole genome sequencing of 5hmC in wild-type versus Lsh knock-out MEFs and ESCs showed that in absence of Lsh, some regions of the genome gain 5hmC while others lose it, with not much effect on gene expression. We further show that 5hmC modifications upon Lsh loss is not a direct consequence of 5mC decrease, as differentially hydroxymethylated regions (DhMR) did not overlap with DMR (differentially methylated regions), underlying that these modifications occurred at different genomic loci. Altogether, our results suggest that LSH is a key regulator of 5hmC in both MEFs and ESC and that TET proteins rely on specific factors to establish genome-wide 5hmC patterns.
Ubiquitin Dynamics in Stem Cell Biology: Current Challenges and Perspectives
Ubiquitination plays a central role in the regulation of stem cell self‐renewal, propagation, and differentiation. In this review, the functions of ubiquitin dynamics in a myriad of cellular processes, acting along side the pluripotency network, to regulate embryonic stem cell identity are highlighted. The implication of deubiquitinases (DUBs) and E3 Ubiquitin (Ub) ligases in cellular functions beyond protein degradation is reported, including key functions in the regulation of mRNA stability, protein translation, and intra‐cellular trafficking; and how it affects cell metabolism, the micro‐environment, and chromatin organization is discussed. Finally, unsolved issues in the field are emphasized and will need to be tackled in order to fully understand the contribution of ubiquitin dynamics to stem cell self‐renewal and differentiation.
Ubiquitin Dynamics in Stem Cell Biology: Current Challenges and Perspectives
Ubiquitination plays a central role in the regulation of stem cell self‐renewal, propagation, and differentiation. In this review, the functions of ubiquitin dynamics in a myriad of cellular processes, acting along side the pluripotency network, to regulate embryonic stem cell identity are highlighted. The implication of deubiquitinases (DUBs) and E3 Ubiquitin (Ub) ligases in cellular functions beyond protein degradation is reported, including key functions in the regulation of mRNA stability, protein translation, and intra‐cellular trafficking; and how it affects cell metabolism, the micro‐environment, and chromatin organization is discussed. Finally, unsolved issues in the field are emphasized and will need to be tackled in order to fully understand the contribution of ubiquitin dynamics to stem cell self‐renewal and differentiation.